Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Clevenbergh

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 11, 2002
Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infectionsB Byl, P Clevenbergh, A Kentos, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 2, 2000
Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT studyC Chaix, C Grenier-Sennelier, P Clevenbergh, et al.
HIV Clinical Trials|April 3, 2003
Variable virological outcomes according to the center providing antiretroviral therapy within the PharmAdapt clinical trialP Clevenbergh, M C Bozonnat, M Kirstetter, et al.
Infectious Diseases Now|November 9, 2020
Compassionate use of cefiderocol in a pancreatic abscess and emergence of resistanceC Grande Perez, E Maillart, V Y Miendje Deyi, et al.
Journal of Clinical Microbiology|January 1, 1997
Molecular epidemiology of an outbreak of multidrug-resistant Enterobacter aerogenes infections and in vivo emergence of imipenem resistanceY De Gheldre, N Maes, F Rost, et al.
The Journal of Infection|July 9, 2002
Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimenP Clevenbergh, M Corcostegui, D Gérard, et al.
Infectious Diseases (London, England)|June 5, 2020
A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquineE Maillart, S Leemans, H Van Noten, et al.
AIDS (London, England)|August 10, 2000
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt StudyJ Durant, P Clevenbergh, R Garraffo, et al.
Antiviral Therapy|June 10, 2000
Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-upP Clevenbergh, J Durant, P Halfon, et al.
HIV Clinical Trials|December 26, 2002
Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavirS Chaillou, J Durant, R Garraffo, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 11, 2002
Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infectionsB Byl, P Clevenbergh, A Kentos, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 2, 2000
Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT studyC Chaix, C Grenier-Sennelier, P Clevenbergh, et al.
HIV Clinical Trials|April 3, 2003
Variable virological outcomes according to the center providing antiretroviral therapy within the PharmAdapt clinical trialP Clevenbergh, M C Bozonnat, M Kirstetter, et al.
Infectious Diseases Now|November 9, 2020
Compassionate use of cefiderocol in a pancreatic abscess and emergence of resistanceC Grande Perez, E Maillart, V Y Miendje Deyi, et al.
Journal of Clinical Microbiology|January 1, 1997
Molecular epidemiology of an outbreak of multidrug-resistant Enterobacter aerogenes infections and in vivo emergence of imipenem resistanceY De Gheldre, N Maes, F Rost, et al.
The Journal of Infection|July 9, 2002
Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimenP Clevenbergh, M Corcostegui, D Gérard, et al.
Infectious Diseases (London, England)|June 5, 2020
A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquineE Maillart, S Leemans, H Van Noten, et al.
AIDS (London, England)|August 10, 2000
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt StudyJ Durant, P Clevenbergh, R Garraffo, et al.
Antiviral Therapy|June 10, 2000
Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-upP Clevenbergh, J Durant, P Halfon, et al.
HIV Clinical Trials|December 26, 2002
Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavirS Chaillou, J Durant, R Garraffo, et al.
Pageof 4